Skip to content

Efficacy of Extract of Trigonella Foenum-graceum as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women

Efficacy of Extract of Trigonella Foenum-graceum (Fenugreek) as Topical Phytoestrogen in Skin Aging Treatment of Post Menopausal Women : A Study of COL1A1, COL3A1, Skin Thickness, and Skin Wrinkles

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04123743
Enrollment
21
Registered
2019-10-11
Start date
2019-08-10
Completion date
2019-11-10
Last updated
2020-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging

Brief summary

Skin is subjected to intrinsic aging and extrinsic aging. Intrinsic aging is influenced by genetic and hormonal factors. Estrogen has significant role in modulating skin physiology. In post menopausal women, skin aging is accelerated because of hypoestrogenism. Administration of estrogen can delay the process of skin aging. Phytoestrogens are estrogen-like compounds which can be found naturally in plants. The investigators intend to study the efficacy of Trigonella foenum-graceum extract as topical phytoestrogen in skin aging treatment of post menopausal women.

Detailed description

In this double-blinded unmatched randomized controlled trial, the investigators intend to study the efficacy of Trigonella foenum-graceum extract as topical phytoestrogen in skin aging treatment of post menopausal women. The investigators have gathered 21 participants that will be divided into 2 groups, experimental group and control group. Experimental group will get treatment with topical cream containing Trigonella foenum-graceum extract, while control group will get treatment with placebo cream. The study will be held in esthetic cluster, Kencana Cipto Mangunkusumo Hospital, and radiology cluster, Kencana Cipto Mangunkusumo Hospital from August 2019 until November 2019.

Interventions

DRUGTrigonella foenum-graceum extract topical cream

Topical cream containing Trigonella foenum-graceum extract

Wardah brand facial wash

OTHERSunscreen Cream

Parasol sunscreen cream SPF 33

OTHERPlacebo

Placebo topical cream

Sponsors

Indonesia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Blinding is done to the participants, care providers, investigator, and outcomes assessor in every stage of the study.

Intervention model description

The participants will be divided into 2 groups, experimental group and control group. Experimental group will get intervention with topical cream containing Trigonella foenum-graceum extract, while control group will get intervention with placebo topical cream. Both experimental and control group will receive Wardah brand facial wash and Parasol sunscreen SPF 33 as part of the assigned intervention as well.The participants will undergo the assigned intervention for 12 weeks.

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
Yes

Inclusion criteria

* Women with minimum 2 years post menopausal and maximum 8 years post menopausal * Have skin aging problems that manifested as wrinkles on forehead, crow's feet, and nasolabial fold region * Estradiol level \< 30 pg/mL * Willing to terminate the routine use of facial cream or treatment during the study duration and at least for 30 days before the study commence * Willing to follow the study protocol and sign the informed consent

Exclusion criteria

* Dermatitis in the region of face * Using oral/topical hormonal supplement in the last 12 months * Using products containing retinoic acid or it's derivatives in the last 30 days * Underwent radiotherapy, facelift, dermabrasion, botox, or facial filler procedures in the last 5 years * Breast lump or other breast abnormality * History of cancer or malignancy * Vein thrombosis * History of hormonal contraception allergy * History of ovariectomy

Design outcomes

Primary

MeasureTime frameDescription
Visual Analogue Scale for Forehead WrinklesChange from initial visit VAS at 12 weeksVisual Analogue Scale (VAS) to measure wrinkles in the forehead region (Scale 0-8, with 0-2 categorized as mild wrinkling, 3-5 categorized as moderate wrinkling, and 6-8 categorized as severe wrinkling)
Visual Analogue Scale for Crow's Feet WrinklesChange from initial visit VAS at 12 weeksVisual Analogue Scale (VAS) to measure wrinkles in crow's feet region (Scale 0-6), with 0-2 categorized as mild wrinkling, 3-4 categorized as moderate wrinkling, and 5-6 categorized as severe wrinkling
Visual Analogue Scale for Nasolabial WrinklesChange from initial visit VAS at 12 weeksVisual Analogue Scale (VAS) to measure wrinkles in nasolabial region (Scale 0-6), with 0-2 categorized as mild wrinkling, 3-4 categorized as moderate wrinkling, and 5-6 categorized as severe wrinkling
High Resolution UltrasoundChange from initial visit dermis thickness at 12 weeksHigh resolution ultrasound examination in bilateral cheek region to determine dermis thickness (in milimeter).

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026